Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series
- 663 Downloads
Treatment of leptomeningeal metastasis (LMD) remains challenging due to advanced systemic disease at presentation and limited treatment options. All patients underwent standard pre-treatment LMD evaluation including CSF assessment (cytology or flow cytometry), brain and spine MR imaging, and radioisotope CSF flow study. DepoCyt (liposomal cytarabine) was administered intraventricularly (n = 80) or intralumbar (n = 40) at 50 mg every 2 weeks ×4 and then every 4 weeks ×6 in responding patients. Dexamethasone (4 mg orally twice per day ×5 days) was co-administered with each DepoCyt treatment. Patients were seen with each DepoCyt treatment and assessed for toxicity. 120 adult patients [median age 51 years (range 33–68)] with LMD were treated with DepoCyt. DepoCyt Common Toxicity Criteria ≥Grade 3 neurotoxicity was seen in 60 cycles (11.5 %) in 28 patients (23.3 %). Toxicity included bacterial meningitis (3.75 % of ventricular treatments: 0 % of lumbar treatments); chemical meningitis (17.5:15 %); communicating hydrocephalus (3.75:5 %); conus medullaris/cauda equina syndrome (5:5 %); decreased visual acuity (5:2.5 %); encephalopathy (5:5 %); leukoencephalopathy (7.5:2.5 %); myelopathy (2.5:2.5 %); radiculopathy (1.25:5 %); and seizures (1.25:2.5 %). Distribution of toxicity was similar regardless of route of administration (ventricular vs. lumbar). Toxicities were transient in 34 episodes (57 %) and permanent in 26 (43 %). There were no treatment-related deaths however 20 treatment-related toxicities (32.2 %) required hospitalization. In this retrospective case series, DepoCyt is generally well tolerated however a subset of patients (12.5 %) not easily identified pre-treatment, develop serious treatment-related neurological complications that may be persistent and impact quality of life.
KeywordsLiposomal cytarabine Leptomeningeal metastases Intra-CSF chemotherapy Neurotoxicity Treatment-related toxicity
Conflict of interest
The author reports no conflict of interest.
- 4.Shapiro WR, Schmid M, Glantz M, Miller JJ (2006) A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 24(6 Suppl):1528 (abstract)Google Scholar
- 8.Goekbuget N, Hartog CM, Bassan R, Derigs HG, Dombret H, Greil R, Hernandez-Rivas JM, Huguet F, Intermesoli T, Jourdan E, Junghanss C, Leimer L, Moreno MJ, Reichle A, Ribera JM, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D (2010) Liposomal ara-C is effective and tolerable in the treatment of CNS relapse of acute lymphoblastic leukemia (ALL) and aggressive lymphoma. Haematologica [Epub Ahead of Print]Google Scholar
- 18.Jabbour E, O’Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA (2007) Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood [Epub Ahead of Print]Google Scholar
- 20.Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, Fernández-Torrón R, Irimia P, Rodríguez-Otero P, Panizo C, Martínez-Vila E (2010) Neurologic complications of intrathecal liposomal cytarabine administered prophylactic ally to patients with non-Hodgkin’s lymphoma. J Neurooncol [Epub Ahead of Print]Google Scholar
- 21.Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U (2010) Neurological complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol [Epub Ahead of Print]Google Scholar